Inhibiting Mycobacterium tuberculosis within and without.
Tuberculosis remains a scourge of global health with shrinking treatment options due to the spread of drug-resistant strains of Mycobacterium tuberculosis Intensive efforts have been made in the past 15 years to find leads for drug development so that better, more potent drugs inhibiting new targets could be produced and thus shorten treatment duration. Initial attempts focused on repurposing drugs that had been developed for other therapeutic areas but these agents did not meet their goals in clinical trials. Attempts to find new lead compounds employing target-based screens were unsuccessful as the leads were inactive against M. tuberculosis Greater success was achieved using phenotypic screening against live tubercle bacilli and this gave rise to the drugs bedaquiline, pretomanid and delamanid, currently in phase III trials. Subsequent phenotypic screens also uncovered new leads and targets but several of these targets proved to be promiscuous and inhibited by a variety of seemingly unrelated pharmacophores. This setback sparked an interest in alternative screening approaches that mimic the disease state more accurately. Foremost among these were cell-based screens, often involving macrophages, as these should reflect the bacterium's niche in the host more faithfully. A major advantage of this approach is its ability to uncover functions that are central to infection but not necessarily required for growth in vitro For instance, inhibition of virulence functions mediated by the ESX-1 secretion system severely attenuates intracellular M. tuberculosis, preventing intercellular spread and ultimately limiting tissue damage. Cell-based screens have highlighted the druggability of energy production via the electron transport chain and cholesterol metabolism. Here, I review the scientific progress and the pipeline, but warn against over-optimism due to the lack of industrial commitment for tuberculosis drug development and other socio-economic factors.This article is part of the themed issue 'The new bacteriology'.
Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Station 19, 1015 Lausanne, Switzerland stewart.cole@epfl.ch.
Stewart T
ST
Cole
D000995:Antitubercular Agents / Q000032:analysis / Q000494:pharmacology*; D055808:Drug Discovery; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000502:physiology; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents
antibiotics; drug discovery; drug resistance; phagocytes; tuberculosis
Tuberculosis (Edinb). 2013 Nov;93(6):569-88
24119636
Drug Discov Today. 2005 Jan 15;10(2):139-47
15718163
Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130430
24821916
Nature. 2012 May 23;485(7399):439-40
22622552
Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):E7073-82
26644565
J Immunol. 2007 Mar 1;178(5):3143-52
17312162
Curr Opin Chem Biol. 2011 Aug;15(4):534-9
21684803
Nat Chem Biol. 2012 Feb 19;8(4):334-41
22344175
Nat Rev Drug Discov. 2013 May;12(5):388-404
23629506
Cell Host Microbe. 2015 Jun 10;17(6):799-810
26048138
Tuberculosis (Edinb). 2009 Sep;89(5):354-63
19783214
Antimicrob Agents Chemother. 2014 Nov;58(11):6413-23
25136022
Nature. 1998 Jun 11;393(6685):537-44
9634230
Bioorg Med Chem. 2015 Dec 15;23 (24):7694-710
26643218
PLoS One. 2008;3(10):e3496
18946503
PLoS One. 2014 May 09;9(5):e97148
24817274
Sci Transl Med. 2013 Dec 4;5(214):214ra168
24307692
PLoS One. 2012;7(12):e52951
23300833
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):E3243-51
25049412
PLoS Pathog. 2008 Feb 8;4(2):e33
18282096
Nat Rev Drug Discov. 2007 Jan;6(1):29-40
17159923
ACS Chem Biol. 2015 Mar 20;10(3):705-14
25427196
Bioorg Med Chem Lett. 2015 Aug 15;25(16):3234-45
26087937
Antimicrob Agents Chemother. 2014 Nov;58(11):6962-5
25155596
J Med Chem. 2014 Apr 10;57(7):3126-39
24568559
Lancet. 2012 Sep 15;380(9846):986-93
22828481
Tuberculosis (Edinb). 2010 Nov;90(6):354-60
20934382
J Bacteriol. 2013 Jan;195(1):66-75
23104803
PLoS Med. 2006 Nov;3(11):e466
17132069
Antimicrob Agents Chemother. 2014 Sep;58(9):5325-31
24957839
PLoS One. 2013 Apr 17;8(4):e60933
23613759
ACS Chem Biol. 2012 Aug 17;7(8):1377-84
22577943
Curr Pharm Des. 2014;20(27):4379-403
24245764
PLoS Pathog. 2015 Feb 12;11(2):e1004679
25675247
Nat Commun. 2015 Jul 09;6:7659
26158909
EMBO Mol Med. 2014 Feb;6(2):158-68
24401837
Nat Commun. 2013;4:2907
24352433
Future Microbiol. 2012 Jul;7(7):823-37
22827305
Nat Chem Biol. 2013 Aug;9(8):499-506
23770708
Chem Biol. 2014 Dec 18;21(12):1660-9
25467124
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2510-7
23776209
N Engl J Med. 2014 Oct 23;371(17):1588-98
25337748
Tuberculosis (Edinb). 2015 Jun;95 Suppl 1:S150-4
25732627
Antimicrob Agents Chemother. 2012 Jan;56(1):324-31
22024828
Antimicrob Agents Chemother. 2015 Aug;59(8):4436-45
25987613
ACS Chem Biol. 2015 Jul 17;10(7):1631-6
25906160
N Engl J Med. 2014 Oct 23;371(17):1642-3
25337754
ACS Med Chem Lett. 2013 Jul 11;4(7):675-679
23930153
Mol Microbiol. 2014 Apr;92(1):194-211
24517327
Lancet. 2013 Mar 23;381(9871):1021-8
23391465
Science. 2005 Jan 14;307(5707):223-7
15591164
ChemMedChem. 2013 Feb;8(2):313-21
23307663
Nature. 2000 Jun 22;405(6789):962-6
10879539
PLoS Pathog. 2009 Oct;5(10):e1000645
19876393
N Engl J Med. 2014 Oct 23;371(17):1577-87
25196020
Cell Host Microbe. 2014 Oct 8;16(4):538-48
25299337
EMBO Mol Med. 2014 Mar;6(3):372-83
24500695
PLoS One. 2013 Sep 23;8(9):e75245
24086479
Future Med Chem. 2010 Aug;2(8):1283-93
21426019
Am J Respir Crit Care Med. 2004 Feb 1;169(3):421-6
14578218
PLoS Pathog. 2012 Feb;8(2):e1002507
22319448
Curr Opin Microbiol. 2009 Feb;12(1):4-10
19155186
Science. 2009 May 8;324(5928):801-4
19299584
J Med Chem. 2014 Jun 12;57(11):4761-71
24818517
PLoS Pathog. 2009 Oct;5(10):e1000507
19876390
Nat Med. 2013 Sep;19(9):1157-60
23913123
Int J Tuberc Lung Dis. 2008 Feb;12(2):128-38
18230244
J Bacteriol. 2006 Nov;188(22):7778-84
16980473
Bioorg Med Chem. 2011 Jun 1;19(11):3483-91
21546254
PLoS Pathog. 2015 Feb 06;11(2):e1004650
25658322
Euro Surveill. 2016;21(10):null
26987893
Tuberculosis (Edinb). 2009 Sep;89(5):334-53
19758845
Nat Rev Drug Discov. 2015 Aug;14(8):511-2
26184493
Biochim Biophys Acta. 2014 Aug;1843(8):1707-16
24263244
N Engl J Med. 2014 Oct 23;371(17):1599-608
25337749